Sector: Health Care
Director information for REGENERON PHARMACEUTICALS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Arthur F. Ryan | Director; Chair | 83 | ["Former Chief Executive Officer and Chair of the Board of Prudential Financial, Inc. from 1994 to 2008","President and Chief Operating Officer of Chase Manhattan Bank from 1990 to 1994","Managed Chase’s worldwide retail bank between 1984 and 1990","Non‑executive director of the Royal Bank of Scotland Group plc from 2008 to 2013","Director of Citizens Financial Group, Inc. from 2009 to 2019"] | ["Audit Committee","Corporate Governance and Compliance Committee"] | 2026 |
| Bonnie L. Bassler, Ph.D. | Director | 63 | ["Andrew K. Golden University Professor since 2025, Squibb Professor in Molecular Biology since 2003","Former Chair of the Department of Molecular Biology from 2013 to 2015 at Princeton University","Howard Hughes Medical Institute Investigator","Former President of the American Society for Microbiology","Former member of the board of the American Association for the Advancement of Science","National Science Foundation board member","American Academy of Microbiology member","U.S. National Medal of Science recipient","MacArthur Foundation Fellowship recipient","Lounsbery Award recipient","Shaw Prize for Life Science and Medicine recipient","Gruber Prize in Genetics recipient","Wolf Prize in Chemistry recipient","Canada Gairdner International Award recipient","Former director of Kaleido Biosciences, Inc. and Cidara Therapeutics, Inc."] | ["Corporate Governance and Compliance Committee","Technology Committee"] | 2026 |
| Christine A. Poon | Lead Independent Director | 73 | ["Former Executive-in-Residence in the Department of Management and Human Resources at The Ohio State University","Former Dean and John W. Berry, Sr. Chair in Business at The Ohio State University","Former Vice Chair and Worldwide Chair of Pharmaceuticals at Johnson & Johnson","Senior leadership positions at Bristol-Myers Squibb Company","Former member of the Supervisory Board of Royal Philips Electronics","Former board member at Decibel Therapeutics, Inc. and The Sherwin-Williams Company","Industry experience in pharmaceuticals","Business strategy and operations experience"] | ["Compensation Committee","Corporate Governance and Compliance Committee"] | 2026 |
| Craig B. Thompson, M.D. | Director | 73 | ["Former President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center from 2010 to 2022","Co‑founder of Agios Pharmaceuticals, Inc.","Former director of Merck & Co., Inc.","Industry Experience","Executive/Leadership Experience","Science/Biotech Background","Research/Academic Experience","Business Strategy/Operations Experience","Financial Expertise","Member of The National Academy of Sciences","Member of The National Academy of Medicine","Member of The American Academy of Arts and Sciences","Member of The American Society for Clinical Investigation","Member of The Association of American Physicians","Board member of Charles River Laboratories International, Inc."] | ["Corporate Governance and Compliance Committee","Technology Committee"] | 2026 |
| David P. Schenkein, M.D. | Director | 68 | ["General Partner and Co‑lead of the Life Sciences team of GV (formerly Google Ventures) since 2019","Adjunct attending physician in hematology at Tufts Medical Center since 2009","Former President, Chief Executive Officer, Chair, and director of Agios Pharmaceuticals, Inc.","Former Senior Vice President, Clinical Hematology/Oncology at Genentech Inc.","Former Adjunct Clinical Professor of Medical Oncology at Stanford University School of Medicine","Former Senior Vice President of Clinical Research at Millennium Pharmaceuticals, Inc.","Former director of Foundation Medicine, Inc. and bluebird bio, Inc.","Extensive leadership experience as an executive and corporate director in the pharmaceutical and healthcare industries","Considerable research and academic experience"] | ["Compensation Committee","Technology Committee"] | 2026 |
| George D. Yancopoulos, M.D., Ph.D. | Co-Chair of the Board; Board co-Chair, President and Chief Scientific Officer | 66 | ["Founding scientist of the Company","President and Chief Scientific Officer of the Company","11th most highly cited scientist in the world in the 1990s","Principal inventor and/or developer of 13 FDA-approved drugs","Founding scientist of the company","Co-Chair of the Board since 2023","M.D. and Ph.D. from Columbia University","Member of the National Academy of Sciences","Principal inventor/developer of 13 FDA-approved drugs"] | ["Technology Committee"] | 2026 |
| George L. Sing | Director | 76 | ["Chief Executive Officer of GanD, Inc. since 2016","Chair of Grace Science, LLC since 2017","Extensive venture capital and leadership experience in the biotechnology sector and high technology","Healthcare venture capital investor","Biomedical company chief executive officer","Executive leadership experience","Substantial knowledge of the Company"] | ["Audit Committee","Compensation Committee"] | 2026 |
| Huda Y. Zoghbi, M.D. | Director | 71 | ["Professor in the Departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine since 1994","Director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital","Howard Hughes Medical Institute Investigator","Breakthrough Prize in Life Sciences","Pearl Meister Greengard Prize","March of Dimes Prize in Developmental Biology","Vanderbilt Prize in Biomedical Science"] | ["Compensation Committee","Technology Committee"] | 2026 |
| Joseph J. LaRosa | Executive Vice President, General Counsel and Secretary | 67 | ["Senior Vice President, General Counsel and Secretary at Nycomed US Inc.","corporate officer at Schering-Plough Corporation","member of the Operations Management Team","J.D. from New York University School of Law"] | ["board of directors","executive committee"] | 2026 |
| Joseph L. Goldstein, M.D. | Director | 85 | ["Regental Professor of Molecular Genetics and Internal Medicine","Chair of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center","Member of the boards of trustees of The Rockefeller University and the Howard Hughes Medical Institute","Nobel Prize for Physiology or Medicine in 1985","U.S. National Medal of Science in 1988","Member of The National Academy of Sciences","Member of The National Academy of Medicine","Member of The Royal Society of London"] | ["Corporate Governance and Compliance Committee","Technology Committee"] | 2026 |
| Kathryn Guarini, Ph.D. | Director; Chair | 54 | ["Former Chief Information Officer of International Business Machines Corporation (IBM) from 2021 to 2023","Vice President, Chief Operating Officer of IBM Research from 2020 to 2021","Vice President, Industry Research of IBM Research from 2018 to 2020","Vice President, Research Strategy of IBM Research from 2017 to 2018","Vice President, Product Management of IBM Systems from 2014 to 2016","Executive/Leadership Experience","Technology/Digital Experience","Science/Biotech Background","Business Strategy/Operations Experience","Research/Academic Experience"] | ["Audit Committee"] | 2026 |
| Leonard S. Schleifer, M.D., Ph.D. | Board co-Chair, President and Chief Executive Officer | 73 | ["Founded the Company in 1988","Built and managed the Company for 38 years","Director, President, and Chief Executive Officer since inception","Co‑Chair of the Board since 2023","Former Chair of the Board from 1990 through 1994","Licensed physician certified in Neurology","Founded the company","Co-Chair of the Board since 2023","Previous Chair of the Board from 1990 to 1994","M.D. and Ph.D. in Pharmacology from the University of Virginia","Licensed physician","Certified in Neurology by the American Board of Psychiatry and Neurology"] | ["Technology Committee"] | 2026 |
| Michael S. Brown, M.D. | Director; Chair | 85 | ["Nobel Prize for Physiology or Medicine in 1985","U.S. National Medal of Science in 1988","Distinguished Chair in Biomedical Sciences","Regental Professor of Molecular Genetics and Internal Medicine","Director of the Jonsson Center for Molecular Genetics"] | ["Corporate Governance and Compliance Committee","Technology Committee"] | 2026 |
| N. Anthony Coles, M.D. | Chair and CEO of TRATE Enterprises LLC | 65 | ["Chair and CEO of TRATE Enterprises LLC since 2013","Former Chair and President and CEO of Cerevel Therapeutics Holdings, Inc.","Former CEO and Chair of Yumanity Therapeutics, Inc.","Former President and CEO of Onyx Pharmaceuticals, Inc.","Former President, CEO, and member of the board of NPS Pharmaceuticals, Inc.","Various leadership positions in biopharmaceutical and pharmaceutical industries","Former director of Laboratory Corporation of America Holdings, Campus Crest Communities, Inc., CRISPR Therapeutics AG, and McKesson Corporation"] | ["Audit Committee","Compensation Committee"] | 2026 |
